Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.
The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.
The immunoassay firm plans to first develop cardiovascular IVDs on its Clarity instrument, followed by assays in oncology and infectious disease.
Through their arrangement, Singulex has granted Grifols an exclusive license to its single-molecule counting technology for use in blood donor and plasma screening.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
The deal gives EMD Millipore control of Singulex's single-molecule counting technology for research applications.
The Biomarker Development Center will use Singulex's Single Molecule Counting technology to quantify ultra-low level biomarkers.
The partners will develop biomarkers for potential use in drug development targeting the disease.
Singulex has appointed Peter Heseltine as chief medical officer.
NEW YORK (GenomeWeb News) – Sony DADC Austria and Singulex today announced a supply agreement for the design and manufacture of customized detection vessels by Sony DADC BioSciences for Singulex's Sgx Clarity System.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.